Cargando…

Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A(2) (Lp-PLA(2)) Inhibitor [(18)F]GSK2647544 in Healthy Male Subjects

PURPOSE: GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), which was in development as a potential treatment for Alzheimer’s disease (AD). In order to refine therapeutic dose predictions and confirm brain penetration, a radiolabelled form of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huiban, Mickael, Coello, Christopher, Wu, Kai, Xu, Yanmei, Lewis, Yvonne, Brown, Andrew P., Buraglio, Mauro, Guan, Chenbing, Shabbir, Shaila, Fong, Regan, Passchier, Jan, Rabiner, Eugenii A., Lockhart, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209404/ https://www.ncbi.nlm.nih.gov/pubmed/27402093 http://dx.doi.org/10.1007/s11307-016-0982-5

Ejemplares similares

Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
por: Wu, Kai, et al.
Publicado: (2016)

An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M(1)) positive allosteric modulator in the living human brain using positron emission tomography
por: Ridler, Khanum, et al.
Publicado: (2014)

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2 )(Lp-PLA(2 )): a review
por: Silva, Isis T, et al.
Publicado: (2011)

Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)): A Novel and Promising Biomarker for Cardiovascular Risks Assessment
por: Cai, Anping, et al.
Publicado: (2013)

Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
por: Karakas, Mahir, et al.
Publicado: (2010)

Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease
por: Diaconu, Adriana, et al.
Publicado: (2020)

First evaluation of PET-based human biodistribution and radiation dosimetry of (11)C-BU99008, a tracer for imaging the imidazoline(2) binding site
por: Venkataraman, Ashwin V., et al.
Publicado: (2018)

Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013)

Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014)

Quantification of human brain PDE4 occupancy by GSK356278: A [(11)C](R)-rolipram PET study
por: van der Aart, Jasper, et al.
Publicado: (2017)

Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles
por: Gregson, John M, et al.
Publicado: (2016)

STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A(2) (Lp-PLA(2)) as a biomarker or risk factor for cardiovascular diseases
por: Hassan, Mohamed
Publicado: (2015)

Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention
por: Yin, Yun-jie, et al.
Publicado: (2020)

Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in adolescents: the healthy young cross-sectional study
por: da Silva, Isis T, et al.
Publicado: (2013)

Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes
por: Passaro, Angelina, et al.
Publicado: (2018)

The Relationship between Intracarotid Plaque Neovascularization and Lp (a) and Lp-PLA2 in Elderly Patients with Carotid Plaque Stenosis
por: Sun, Chang, et al.
Publicado: (2022)

Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease
por: Ma, Sha, et al.
Publicado: (2022)

Lipoprotein-associated phospholipase A(2 )(Lp-PLA(2)) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults
por: Detopoulou, Paraskevi, et al.
Publicado: (2009)

Resveratrol Treatment Is Associated with Lipid Regulation and Inhibition of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Rabbits Fed a High-Fat Diet
por: Xu, Lei, et al.
Publicado: (2020)

The Utility of the Lipoprotein-Associated Phospholipase A(2) (Lp-PLA(2)) Assay in Detecting Abnormalities in Lipid Metabolism and Cardiovascular Risk in an HIV-Infected South African Cohort
por: Mayne, Elizabeth S., et al.
Publicado: (2019)

Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia
por: Zheng, Dongdan, et al.
Publicado: (2017)

Lp-PLA(2), a new biomarker of vascular disorders in metabolic diseases
por: De Stefano, Alessandro, et al.
Publicado: (2019)

Association between Lp-PLA2 and coronary heart disease in Chinese patients
por: Yang, Li, et al.
Publicado: (2017)

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance
por: Wang, Guo-Hua, et al.
Publicado: (2021)

Homocysteine and Lp-PLA2 levels: Diagnostic value in coronary heart disease
por: Wu, Linlin, et al.
Publicado: (2023)

Prehypertension-Associated Elevation in Circulating Lysophosphatidlycholines, Lp-PLA(2) Activity, and Oxidative Stress
por: Kim, Minjoo, et al.
Publicado: (2014)

Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids
por: Jackisch, Laura, et al.
Publicado: (2018)

Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis
por: Deng, Mingming, et al.
Publicado: (2021)

Association of Carotid Plaque and Serum Lipoprotein-Associated Phospholipase A2 (LP-PLA2) with Postoperative Delirium in Geriatric Patients Undergoing Hip Replacement: A Prospective Cohort Study
por: Wan, Tiantian, et al.
Publicado: (2020)

Lp-PLA(2) activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study
por: Siddiqui, Moneeza K., et al.
Publicado: (2018)

Genome-Wide Association Study of Lp-PLA(2) Activity and Mass in the Framingham Heart Study
por: Suchindran, Sunil, et al.
Publicado: (2010)

Association of Lp-PLA(2) Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients
por: Wang, Yan, et al.
Publicado: (2015)

Lp-PLA(2) activity and mass and CRP are associated with incident symptomatic peripheral arterial disease
por: Fatemi, Shahab, et al.
Publicado: (2019)

On the present and future role of Lp-PLA(2) in atherosclerosis-related cardiovascular risk prediction and management
por: Fras, Zlatko, et al.
Publicado: (2020)

Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations
por: Song, K, et al.
Publicado: (2012)

Progranulin inhibits phospholipase sPLA2-IIA to control neuroinflammation
por: Du, Huan, et al.
Publicado: (2023)

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement
por: Zheng, Dongdan, et al.
Publicado: (2014)

Lp‐PLA(2), Plaque Inflammation and Lesion Development Vary Fundamentally Between Different Vascular Sites
por: Marsche, Gunther
Publicado: (2015)

Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection
por: Dua, Pamila, et al.
Publicado: (2022)

The association between circulating Hcy and Lp-PLA2 levels and poststroke depression: A meta-analysis
por: Tao, Yongjun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o08ru770h68kj3ul1od9j21ns2